Efficacy of mitoxantrone in neuromyelitis optica spectrum: Clinical and neuroradiological study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 5, 2013, Pages 511-516

  Cabre, Philippe ^a   Olindo, Stephane ^a   Marignier, Romain ^b   Jeannin, Severine ^a   Merle, Harold ^a   Smadja, Didier ^a  

^a CHRU Pierre Zobda Quitman ^*  (Martinique)

^b HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; GADOLINIUM; METHYLPREDNISOLONE; MITOXANTRONE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALOPECIA; ARTICLE; CARDIOTOXICITY; CLINICAL STUDY; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOOPTIC NEUROPATHY; NAIL DISEASE; NAUSEA; NEURORADIOLOGY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SECONDARY AMENORRHEA; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VOMITING;

EID: 84876118283     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-303121     Document Type: Article

References (33)

1. Cabre P, González-Quevedo A, Bonnan M, et al. Relapsing neuromyelitis optica: long term clinical history and clinical predictors of death. J Neurol Neurosurg Psychiatry 2009;80:1162-4.
2. Uzawa A, Mori M, Hayakawa S, et al. Different responses to betaferon-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010;17:672-6.
3. Cree BA, Lamb S, Morgan K, et al. An open labelled study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-2.
4. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13:256-9. (Pubitemid 46592781)
5. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and aziathioprime. Neurology 1998;51:1219-20. (Pubitemid 28473439)
6. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate: retrospective analysis of 24 patients. Arch Neurol 2009;66:1128-33.
7. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-8.
8. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone treatment for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957-63. (Pubitemid 44036296)
9. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011;68:473-9.
10. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61. (Pubitemid 34755161)
11. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds the aquaporin-4 water channel. J Exp Med 2005;202:433-7.
12. Okada K, Matsushita T, Kira J, et al. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 2010;74:177-8.
13. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008;79:52-6.
14. Edan G, Comi G, Le Page E, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 2011;82:1344-50.
15. Neuhaus O, Wiendl H, Kieseier BC, et al. Multiple sclerosis: mitoxantrone promotes diferential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168:128-37. (Pubitemid 41396410)
16. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9. (Pubitemid 43958540)
17. Bonnan M, Olindo S, Signate A, et al. Neuroradiological aspects of neuromyelitis optica. Rev Neurol 2006;162:595-602.
18. Marignier R, De Sèze J, Vukusic S, et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler 2008;14:440-5. (Pubitemid 351943855)
19. Marignier R, Nicolle A, Watrin C, et al. Neuromyelitis Optica-IgG induces oligodendrocyte injury through astrocyte alteration. Brain 2010;133:2578-91.
20. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008;65:913-19. (Pubitemid 352008474)
21. Singhal BS, Geeta S, Hundalani SG, et al. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. Neurol India 2009;57:418-23.
22. Chan A, Weilbach FX, Toyka KV, et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139:152-8. (Pubitemid 40066141)
23. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092-9. (Pubitemid 46717389)
24. Watanabe S, Misu T, Miyasawa I, et al. Low-dose corticosteroids reduces relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007;13:968-74. (Pubitemid 351541430)
25. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-8. (Pubitemid 27090928)
26. Cabrera-Gómez JA, Bonnan M, González-Quevedo A, et al. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler 2009;15:828-33.
27. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquapporine-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-43. (Pubitemid 47355956)
28. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy and predictors of benefit in neuromyelitis optica. Neurology 2011;77:659-66.
29. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004;63:S28-32. (Pubitemid 40019276)
30. Marriott JJ, Miyasaki JM, Gronseth G, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-70.
31. Ellis R, Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009;15:505-8.
32. Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011;77:1887-95.
33. Le Page E, Leray E, Edan G, et al. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011;17:867-75.